Literature DB >> 21458383

Molecular diagnosis in Ewing family tumors: the Rizzoli experience--222 consecutive cases in four years.

Gabriella Gamberi1, Stefania Cocchi, Stefania Benini, Giovanna Magagnoli, Luca Morandi, Jennifer Kreshak, Marco Gambarotti, Piero Picci, Licciana Zanella, Marco Alberghini.   

Abstract

The Ewing's family of tumors (EFTs) are characterized by chimeric transcripts generated by specific chromosomal rearrangements. The most common fusions are between the EWSR1 gene on chromosome 22 and the ETS family of transcription factors; rarely, FUS (on chromosome 16) substitutes for EWSR1. The detection of specific translocations using molecular analysis is now a routine part of the pathological examination of EFT. Here, we report our experience with molecular diagnosis of EFT during the 4 years (2006-2009) at the Rizzoli Institute. We analyzed 222 consecutive tumors with a presumptive diagnosis of EFT using molecular techniques and IHC. We found five distinct types of EWSR1-FLI1 fusion transcripts resulting from translocation t(11;22), three types of EWSR1-ERG transcripts resulting from t(21;22), and one type of t(2;22) resulting in EWSR1-FEV fusion. Molecular investigation validated 92% of cases ultimately diagnosed as EFT; IHC validated 76% of the cases. Thus, despite the difficulties and limitations associated with both molecular and IHC analysis on fresh and formalin-fixed, paraffin-embedded tissue, a combination of these techniques is the best approach to enhancing the accuracy of EFT diagnosis. We also present our method for choosing which molecular techniques to apply. Finally, we collected the most prevalent breakpoints reported in the literature, indicating which exons are involved, the sequence breakpoints, and the NCBI reference sequences.
Copyright © 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21458383      PMCID: PMC3077725          DOI: 10.1016/j.jmoldx.2011.01.004

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  61 in total

1.  Molecular characterization of the genomic breakpoint junction in a t(11;22) translocation in Ewing sarcoma.

Authors:  K Obata; H Hiraga; T Nojima; M C Yoshida; S Abe
Journal:  Genes Chromosomes Cancer       Date:  1999-05       Impact factor: 5.006

Review 2.  Difficulties in diagnosing small round cell tumours of childhood from fine needle aspiration cytology samples.

Authors:  Ziva Pohar-Marinsek
Journal:  Cytopathology       Date:  2008-04       Impact factor: 2.073

3.  Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases.

Authors:  Andrew L Folpe; John R Goldblum; Brian P Rubin; Bahig M Shehata; Wendy Liu; Angelo P Dei Tos; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2005-08       Impact factor: 6.394

4.  A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor.

Authors:  Janos Sumegi; Jun Nishio; Marilu Nelson; Robert W Frayer; Deborah Perry; Julia A Bridge
Journal:  Mod Pathol       Date:  2010-11-26       Impact factor: 7.842

5.  Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.

Authors:  J M Bourgeois; S R Knezevich; J A Mathers; P H Sorensen
Journal:  Am J Surg Pathol       Date:  2000-07       Impact factor: 6.394

6.  Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements.

Authors:  C R Antonescu; A Elahi; J H Healey; M F Brennan; M Y Lui; J Lewis; S C Jhanwar; J M Woodruff; M Ladanyi
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

7.  Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?

Authors:  A Zoubek; B Dockhorn-Dworniczak; O Delattre; H Christiansen; F Niggli; I Gatterer-Menz; T L Smith; H Jürgens; H Gadner; H Kovar
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

8.  Ewing sarcoma-peripheral neuroectodermal tumor of the kidney with a FUS-ERG fusion transcript.

Authors:  Thomas Berg; Ann-Hilde Kalsaas; Jochen Buechner; Lill-Tove Busund
Journal:  Cancer Genet Cytogenet       Date:  2009-10

9.  Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions.

Authors:  Lu Wang; Rohit Bhargava; Tao Zheng; Leonard Wexler; Margaret H Collins; Diane Roulston; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

10.  Pathobiologic markers of the ewing sarcoma family of tumors: state of the art and prediction of behaviour.

Authors:  Alfredo Pinto; Paul Dickman; David Parham
Journal:  Sarcoma       Date:  2010-10-14
View more
  30 in total

Review 1.  [Avoiding pitfalls in the diagnostics of bone neoplasms: importance of reference pathology].

Authors:  M Werner
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Epithelial marker expression does not rule out a diagnosis of Ewing's sarcoma family of tumours.

Authors:  Isidro Machado; Samuel Navarro; Jose A López-Guerrero; Marco Alberghini; Piero Picci; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2011-09-02       Impact factor: 4.064

3.  Molecular cytogenetic characterization of two established ESFT cell lines.

Authors:  Masako Ishiguro; Mutsumi Yuki; Tomoko Fukushige; Mikio Mizoguchi; Yasuhiko Kaneko; Takeshita Morishige; Hiroshi Iwasaki
Journal:  Hum Cell       Date:  2016-09-09       Impact factor: 4.174

Review 4.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

Authors:  Marilyn M Li; Michael Datto; Eric J Duncavage; Shashikant Kulkarni; Neal I Lindeman; Somak Roy; Apostolia M Tsimberidou; Cindy L Vnencak-Jones; Daynna J Wolff; Anas Younes; Marina N Nikiforova
Journal:  J Mol Diagn       Date:  2017-01       Impact factor: 5.568

5.  Superficial EWSR1-negative undifferentiated small round cell sarcoma with CIC/DUX4 gene fusion: a new variant of Ewing-like tumors with locoregional lymph node metastasis.

Authors:  Isidro Machado; Julia Cruz; Javier Lavernia; Luis Rubio; Jorge Campos; María Barrios; Camille Grison; Virginie Chene; Gaelle Pierron; Olivier Delattre; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2013-11-10       Impact factor: 4.064

6.  Multiple splice variants of EWSR1-ETS fusion transcripts co-existing in the Ewing sarcoma family of tumors.

Authors:  Barbara Patócs; Krisztina Németh; Miklós Garami; Gabriella Arató; Ilona Kovalszky; Miklós Szendrői; György Fekete
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

7.  Clinicopathological and molecular spectrum of ewing sarcomas/PNETs, including validation of EWSR1 rearrangement by conventional and array FISH technique in certain cases.

Authors:  Bharat Rekhi; Ulrich Vogel; Ranjan Basak; Sangeeta B Desai; Nirmala A Jambhekar
Journal:  Pathol Oncol Res       Date:  2013-11-30       Impact factor: 3.201

Review 8.  Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities.

Authors:  Maxime Blijlevens; Jing Li; Victor W van Beusechem
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

9.  Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.

Authors:  Scott A Tomlins; Nallasivam Palanisamy; J Chad Brenner; Jennifer N Stall; Javed Siddiqui; Dafydd G Thomas; David R Lucas; Arul M Chinnaiyan; Lakshmi P Kunju
Journal:  Am J Clin Pathol       Date:  2013-06       Impact factor: 2.493

Review 10.  [Avoiding pitfalls in the diagnostics of bone neoplasms from pathologists point of view : Importance of reference pathology].

Authors:  M Werner
Journal:  Radiologe       Date:  2016-06       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.